Determine cancer risk in Parkinson
- Trial ID
- NCT06814431
- Official Title
- Study on the Incidence of Malignant Neoplasms in Patients with Parkinson's Disease and Heterozygous Mutation of the GBA Gene
- Goal
- Determine cancer risk in Parkinson
- Status
- RECRUITING
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
- Study Type
- OBSERVATIONAL
- Enrollment
- 3000 participants
- Conditions
- Idiopathic Parkinson's Disease (PD)
Plain-Language Summary
Researchers want to know whether people with Parkinson's who carry a single (heterozygous) mutation in the GBA gene have higher rates of malignant cancers than other people with Parkinson's. They will follow about 3,000 adults with Parkinson's, determine who has a heterozygous GBA mutation, and track new cancer diagnoses through medical records and registries; since the work is observational, no experimental treatment is given. GBA makes the enzyme glucocerebrosidase, which helps lysosomes clear cellular waste, and reduced enzyme activity can alter cell biology in ways that might influence cancer risk, so the study is looking for those patterns. Adults 18 and older with Parkinson's confirmed by the UK Brain Bank criteria are eligible, people with an uncertain diagnosis are excluded.
Locations
- Ospedale A. Perrino, Brindisi, Italy
- IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
- Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy
- Ospedale Santa Chiara di Trento, Trento, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. Researchers want to know whether people with Parkinson's who carry a single (heterozygous) mutation in the GBA gene have higher rates of malignant cancers than other people with Parkinson's. They will follow about 3,000 adults with Parkinson's, determine who has a heterozygous GBA mutation, and track new cancer diagnoses through medical records and registries; since the work is observational, no experimental treatment is given. GBA makes the enzyme glucocerebrosidase, which helps lysosomes clear cellular waste, and reduced enzyme activity can alter cell biology in ways that might influence cancer risk, so the study is looking for those patterns. Adults 18 and older with Parkinson's confirmed by the UK Brain Bank criteria are eligible, people with an uncertain diagnosis are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 4 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years.